Genmab raises 2022 sales outlook to top USD 1.6bn

Biotech firm Genmab is once again counting on sales advancements, projecting a revenue of DKK 10.8–12bn (USD 1.6–1.8bn) in the current financial year.

Photo: Tuala Hjarnø / Genmab / PR

Genmab ended 2021 with a revenue of DKK 8.5bn (USD 1.3bn), compared to DKK 10.1bn (USD 1.5bn) in 2020, and an operating profit (EBIT) of DKK 3bn (USD 461m) against DKK 6.3bn (USD 964m) the preceding year, when an extraordinary one-off payment of DKK 4.4bn (USD 672m) from partner Abbvie lifted profits.

The results are in line with expectations. Danish bank Sydbank had projected a 2021 total revenue of DKK 8.4bn (USD 1.3bn) and an EBIT of DKK 3bn (USD 460m).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs